Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07426380 · ClinicalTrials.gov registry record · Phase 1
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
A Phase 1 study of Renal Impairment and Kidney Failure, Chronic, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT07426380: Recruiting Phase 1 study of Renal Impairment and Kidney Failure, Chronic, sponsored by Eli Lilly and Company.
NCT07426380 is a Phase 1 study of Renal Impairment and Kidney Failure, Chronic that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 28 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07426380, a Phase 1 study of Renal Impairment and Kidney Failure, Chronic, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening.
Conditions Studied
Interventions
- DRUG LY3841136
Study Locations (2)
Florida
- Floridian Clinical Research, LLC - Miami Lakes
- Omega Research Orlando LLC - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT07426380 shows while recruiting
NCT07426380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (18% lower).
The record links to 6 conditions, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which LY3841136 is the first listed.
NCT07426380 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07426380 about?
NCT07426380 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function". The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC)...
What is the current status of trial NCT07426380?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-02-24. Estimated completion is 2026-10.
What conditions does trial NCT07426380 study?
This clinical trial studies the following conditions: Renal Impairment, Kidney Failure, Chronic, Kidney Disease, Renal Insufficiency, End-Stage Kidney Disease.
What interventions are being tested in trial NCT07426380?
The interventions under investigation include: LY3841136 (DRUG).
Who is sponsoring clinical trial NCT07426380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07426380 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07426380's enrollment target sits among peer trials
28 16th of 32 higher than 14 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI